Go Pro
→ Your name isn't on our protected list yet (From American Alternative) (Ad)tc pixel Free LUCY Stock Alerts

Innovative Eyewear (LUCY) Competitors

Innovative Eyewear logo
$0.87 -0.09 (-8.88%)
Closing price 07/15/2026 04:00 PM Eastern
Extended Trading
$0.86 -0.01 (-0.88%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LUCY vs. PSTV, NMTC, POAI, CTSO, and LFWD

Should you buy Innovative Eyewear stock or one of its competitors? MarketBeat compares Innovative Eyewear with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innovative Eyewear include Plus Therapeutics (PSTV), NeuroOne Medical Technologies (NMTC), Predictive Oncology (POAI), Cytosorbents (CTSO), and Lifeward (LFWD). These companies are all part of the "medical equipment" industry.

How does Innovative Eyewear compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Innovative Eyewear has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus Therapeutics$5.21M5.39-$22.39M-$2.30N/A
Innovative Eyewear$2.66M2.10-$7.59M-$1.69N/A

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 1.7% of Innovative Eyewear shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Plus Therapeutics and Plus Therapeutics both had 3 articles in the media. Innovative Eyewear's average media sentiment score of 0.54 beat Plus Therapeutics' score of 0.47 indicating that Innovative Eyewear is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Plus Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Innovative Eyewear
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market.

Plus Therapeutics has a net margin of -230.24% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Plus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Plus Therapeutics-230.24% -198.48% -73.13%
Innovative Eyewear -272.42%-83.37%-76.02%

Plus Therapeutics currently has a consensus price target of $56.40, suggesting a potential upside of 1,282.35%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Plus Therapeutics is more favorable than Innovative Eyewear.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Plus Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Innovative Eyewear
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Plus Therapeutics beats Innovative Eyewear on 9 of the 15 factors compared between the two stocks.

How does Innovative Eyewear compare to NeuroOne Medical Technologies?

Innovative Eyewear (NASDAQ:LUCY) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Innovative Eyewear had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Innovative Eyewear and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.94 beat Innovative Eyewear's score of 0.54 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Innovative Eyewear
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeuroOne Medical Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NeuroOne Medical Technologies has higher revenue and earnings than Innovative Eyewear. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovative Eyewear$2.66M2.10-$7.59M-$1.69N/A
NeuroOne Medical Technologies$12.10M1.80-$3.61M-$0.85N/A

Innovative Eyewear has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

NeuroOne Medical Technologies has a net margin of -68.35% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Innovative Eyewear-272.42% -83.37% -76.02%
NeuroOne Medical Technologies -68.35%-99.43%-70.40%

NeuroOne Medical Technologies has a consensus price target of $11.67, suggesting a potential upside of 364.81%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Innovative Eyewear.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovative Eyewear
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

1.0% of Innovative Eyewear shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 1.7% of Innovative Eyewear shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

NeuroOne Medical Technologies beats Innovative Eyewear on 11 of the 16 factors compared between the two stocks.

How does Innovative Eyewear compare to Predictive Oncology?

Innovative Eyewear (NASDAQ:LUCY) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 1.7% of Innovative Eyewear shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Innovative Eyewear has a net margin of -272.42% compared to Predictive Oncology's net margin of -5,065.23%. Innovative Eyewear's return on equity of -83.37% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Innovative Eyewear-272.42% -83.37% -76.02%
Predictive Oncology -5,065.23%-732.73%-235.55%

Innovative Eyewear has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovative Eyewear
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Innovative Eyewear had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for Innovative Eyewear and 0 mentions for Predictive Oncology. Innovative Eyewear's average media sentiment score of 0.54 beat Predictive Oncology's score of 0.00 indicating that Innovative Eyewear is being referred to more favorably in the media.

Company Overall Sentiment
Innovative Eyewear Positive
Predictive Oncology Neutral

Innovative Eyewear has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovative Eyewear$2.66M2.10-$7.59M-$1.69N/A
Predictive Oncology$1.66M14.29-$12.66M-$13.50N/A

Summary

Innovative Eyewear beats Predictive Oncology on 12 of the 14 factors compared between the two stocks.

How does Innovative Eyewear compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 1.7% of Innovative Eyewear shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cytosorbents has a net margin of -31.85% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Cytosorbents' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytosorbents-31.85% -235.57% -37.88%
Innovative Eyewear -272.42%-83.37%-76.02%

Cytosorbents has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market.

Innovative Eyewear has lower revenue, but higher earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytosorbents$37.06M0.66-$8.20M-$0.19N/A
Innovative Eyewear$2.66M2.10-$7.59M-$1.69N/A

In the previous week, Innovative Eyewear had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Innovative Eyewear and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.32 beat Innovative Eyewear's score of 0.54 indicating that Cytosorbents is being referred to more favorably in the media.

Company Overall Sentiment
Cytosorbents Positive
Innovative Eyewear Positive

Cytosorbents currently has a consensus target price of $5.38, suggesting a potential upside of 1,282.10%. Given Cytosorbents' stronger consensus rating and higher probable upside, research analysts clearly believe Cytosorbents is more favorable than Innovative Eyewear.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytosorbents
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Innovative Eyewear
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Cytosorbents beats Innovative Eyewear on 10 of the 16 factors compared between the two stocks.

How does Innovative Eyewear compare to Lifeward?

Innovative Eyewear (NASDAQ:LUCY) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Lifeward has a net margin of -123.66% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Lifeward's return on equity.

Company Net Margins Return on Equity Return on Assets
Innovative Eyewear-272.42% -83.37% -76.02%
Lifeward -123.66%-243.14%-97.39%

Innovative Eyewear has a beta of 2.71, suggesting that its share price is 171% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 1.7% of Innovative Eyewear shares are owned by insiders. Comparatively, 1.5% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Innovative Eyewear has higher earnings, but lower revenue than Lifeward. Innovative Eyewear is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovative Eyewear$2.66M2.10-$7.59M-$1.69N/A
Lifeward$22.03M1.00-$19.91M-$19.66N/A

In the previous week, Innovative Eyewear had 2 more articles in the media than Lifeward. MarketBeat recorded 3 mentions for Innovative Eyewear and 1 mentions for Lifeward. Lifeward's average media sentiment score of 1.53 beat Innovative Eyewear's score of 0.54 indicating that Lifeward is being referred to more favorably in the news media.

Company Overall Sentiment
Innovative Eyewear Positive
Lifeward Very Positive

Lifeward has a consensus price target of $10.00, indicating a potential upside of 28.04%. Given Lifeward's stronger consensus rating and higher probable upside, analysts plainly believe Lifeward is more favorable than Innovative Eyewear.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovative Eyewear
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Lifeward
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Innovative Eyewear and Lifeward tied by winning 8 of the 16 factors compared between the two stocks.

Get Innovative Eyewear News Delivered to You Automatically

Sign up to receive the latest news and ratings for LUCY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LUCY vs. The Competition

Export
MetricInnovative EyewearMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$6.13M$8.31B$6.78B$12.55B
Dividend YieldN/A2.57%2.68%9.45%
P/E Ratio-0.5215.5127.0824.36
Price / Sales2.107.72510.2191.03
Price / CashN/A18.0148.6360.00
Price / Book0.523.3310.946.31
Net Income-$7.59M$228.19M$3.59B$331.55M
7 Day Performance-18.44%-2.50%-1.76%-0.71%
1 Month Performance1.42%-1.91%3.74%0.16%
1 Year Performance-59.78%-0.34%27.47%19.66%

Innovative Eyewear Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LUCY
Innovative Eyewear
0.9052 of 5 stars		$0.87
-8.9%		N/A-59.6%$6.13M$2.66MN/A9
PSTV
Plus Therapeutics
2.4872 of 5 stars		$3.84
-2.2%		$56.40
+1,370.7%		-48.5%$26.39M$5.21MN/A20
NMTC
NeuroOne Medical Technologies
2.8573 of 5 stars		$3.00
-0.7%		$11.67
+288.9%		-40.7%$26.10M$12.10MN/A20
POAI
Predictive Oncology
N/A$7.39
-12.1%		N/A-40.9%$25.08M$1.66MN/A30
CTSO
Cytosorbents
3.4099 of 5 stars		$0.40
-2.4%		$5.38
+1,253.9%		-62.2%$24.95M$37.20MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LUCY) was last updated on 7/16/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
URGENT Dollar Reset Warning for Monday
A 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...
Golden Portfolio | Sponsoredtc pixel
What will Nvidia do next?
Wall Street spends millions on supercomputers and analyst teams to forecast stock prices. Now a new predictive...
TradeSmith | Sponsoredtc pixel
BlackRock just moved $150 billion into this "new internet"
BlackRock CEO Larry Fink's 2026 chairman's letter compared tokenization to the birth of the internet - and the...
Awesomely, LLC | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel